MRNA vs ROIV
Moderna and Roivant Sciences Ltd., both Healthcare
Moderna is the larger company at $25B against $24B. Over the past year ROIV returned +136% against +93% for MRNA. The RyuScore puts MRNA ahead, 48 against 42 out of 100.
| Figure | MRNA | ROIV |
|---|---|---|
| Last close | $62.96 | $35.42 |
| Market cap | $25B | $24B |
| 1-year return | +93% | +136% |
| 5-year return | -81% | +255% |
| RyuScoresector-relative, 1–10 | 48/100 | 42/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Moderna
Revenue of $145M in Q2 2026, net income null. Its largest reported line is COVID19, 63% of the disclosed total.
Roivant Sciences Ltd.
Revenue of $1M in Q1 2026, net income null.
Open these two in the interactive comparison to add more names, change the period or see the correlation.